|
WO1994004680A1
(en)
|
1992-08-21 |
1994-03-03 |
Schering Corporation |
Human interleukin-13
|
|
US5635599A
(en)
|
1994-04-08 |
1997-06-03 |
The United States Of America As Represented By The Department Of Health And Human Services |
Fusion proteins comprising circularly permuted ligands
|
|
DE4423131A1
(de)
*
|
1994-07-01 |
1996-01-04 |
Bayer Ag |
Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
|
|
FR2742156A1
(fr)
|
1995-12-06 |
1997-06-13 |
Sanofi Sa |
Polypeptide recepteur de l'il-13
|
|
US6335426B1
(en)
*
|
1996-06-14 |
2002-01-01 |
Bayer Corporation |
T-cell selective interleukin-4 agonists
|
|
US6028176A
(en)
*
|
1996-07-19 |
2000-02-22 |
Bayer Corporation |
High-affinity interleukin-4 muteins
|
|
AU2001288405B8
(en)
|
1998-04-03 |
2007-06-14 |
The Penn State Research Foundation |
Amino acid substitution mutants of interleukin 13
|
|
US6673602B1
(en)
|
1999-06-11 |
2004-01-06 |
The General Hospital Corporation |
Herpes simplex virus amplicon vector targeting system and method of using same
|
|
US6737511B1
(en)
|
1999-08-16 |
2004-05-18 |
The United States Of America As Represented By The Department Of Health And Human Services |
Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis
|
|
AU780163B2
(en)
|
1999-09-09 |
2005-03-03 |
Merck Sharp & Dohme Corp. |
Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
|
|
WO2001025282A1
(en)
|
1999-10-06 |
2001-04-12 |
The Penn State Research Foundation |
Il13 mutants
|
|
EP1263785A2
(en)
|
1999-11-11 |
2002-12-11 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Mutated il-13 molecules and their uses
|
|
GB0004016D0
(en)
|
2000-02-22 |
2000-04-12 |
Royal Brompton Hospital |
Biological material and uses thereof
|
|
US6333410B1
(en)
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
|
AU2440802A
(en)
|
2000-10-18 |
2002-04-29 |
Massachusetts Inst Technology |
Methods and products related to pulmonary delivery of polysaccharides
|
|
US7087224B2
(en)
|
2000-10-31 |
2006-08-08 |
Amgen Inc. |
Method of treating anemia by administering IL-1ra
|
|
WO2002101629A1
(en)
|
2001-06-07 |
2002-12-19 |
Wyeth |
Solution structure of il-13 and uses thereof
|
|
US20040248260A1
(en)
|
2001-10-26 |
2004-12-09 |
Heavner George A. |
IL-13 mutein proteins, antibodies, compositions, methods and uses
|
|
CA2593648A1
(en)
|
2005-01-10 |
2006-07-13 |
Research Development Foundation |
Targeted chimeric molecules for cancer therapy
|
|
JP5114418B2
(ja)
|
2005-09-09 |
2013-01-09 |
ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ・アズ リプレゼンテッド バイ ザ セクレタリー・デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
細胞死を抑制する又は細胞増殖を高めるための方法及び組成物
|
|
WO2007048019A2
(en)
|
2005-10-20 |
2007-04-26 |
The Penn State Research Foundation |
Delivery system for diagnostic and therapeutic agents
|
|
HUE031156T2
(en)
|
2006-06-07 |
2017-06-28 |
Genzyme Corp |
Gene therapy for amyotrophic lateral sclerosis and other spinal cord disorders
|
|
WO2008101671A2
(en)
|
2007-02-19 |
2008-08-28 |
Apogenix Gmbh |
Il-4 fc fusion proteins
|
|
EP2197909A4
(en)
|
2007-08-24 |
2014-12-03 |
Univ Minnesota |
REAGENTS ON RECIPES
|
|
CN102112144A
(zh)
|
2008-05-16 |
2011-06-29 |
拜耳医药保健有限公司 |
靶向性凝固因子及其使用方法
|
|
WO2010031185A1
(en)
|
2008-09-19 |
2010-03-25 |
Protox Therapeutics Inc. |
Treating cancer stem cells using targeted cargo proteins
|
|
US20100183545A1
(en)
|
2008-10-14 |
2010-07-22 |
The United States Of America, As Represented By The Secretary, |
Targeted cargo protein combination therapy
|
|
JP2010154842A
(ja)
|
2008-12-03 |
2010-07-15 |
Koji Kawakami |
Ｅｇｆｒを標的にした新規抗がんキメラペプチド
|
|
US20110023680A1
(en)
|
2009-07-30 |
2011-02-03 |
Kuo-Chung Wang |
Pcb cutter module with detachable cutters
|
|
TWI397428B
(zh)
|
2009-12-29 |
2013-06-01 |
財團法人工業技術研究院 |
標的第四介白素受體之傳輸系統
|
|
WO2011106779A1
(en)
|
2010-02-26 |
2011-09-01 |
Aerovance Inc. |
Use of modified il-4 mutien receptor antagonists to treat dermatitis
|
|
JP5734951B2
(ja)
|
2010-03-03 |
2015-06-17 |
シャープ株式会社 |
表示装置およびその駆動方法、ならびに液晶表示装置
|
|
AU2011316786A1
(en)
|
2010-10-22 |
2013-05-02 |
Protox Therapeutics Corp. |
Use of human serum albumin to decrease antigenicity of therapeutic proteins
|
|
CA2860170C
(en)
|
2010-12-22 |
2022-06-14 |
The Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
CA2832569A1
(en)
|
2011-04-08 |
2012-10-11 |
Baylor College Of Medicine |
Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
|
|
WO2012139112A1
(en)
|
2011-04-08 |
2012-10-11 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Ubiquitin fusions for improving the efficacy of cytosolic acting targeted toxins
|
|
EP2850093B1
(en)
|
2012-01-27 |
2019-01-09 |
The Board of Trustees of the Leland Stanford Junior University |
Therapeutic il-13 polypeptides
|
|
CN105722860A
(zh)
|
2013-09-24 |
2016-06-29 |
梅迪塞纳医疗股份有限公司 |
白介素-2融合蛋白及其应用
|
|
EP3049526B1
(en)
|
2013-09-24 |
2021-02-24 |
Medicenna Therapeutics, Inc. |
Interleukin-4 receptor-binding fusion proteins and uses thereof
|
|
WO2015070210A1
(en)
|
2013-11-11 |
2015-05-14 |
Wake Forest University Health Sciences |
Epha3 and multi-valent targeting of tumors
|
|
BR112016018100A2
(pt)
|
2014-02-07 |
2018-02-20 |
Univ Mcmaster |
acoplador antigênico de células t trifuncional, métodos e usos do mesmo
|
|
CA2972714A1
(en)
|
2014-09-09 |
2016-03-17 |
Unum Therapeutics |
Chimeric receptors and uses thereof in immune therapy
|
|
BR112017005631A2
(pt)
|
2014-09-19 |
2018-06-26 |
City Of Hope |
células t com receptor de antígeno coestimulador quimérico direcionadas à il13ra2
|
|
JP2017537622A
(ja)
|
2014-12-02 |
2017-12-21 |
ロジャー・ウィリアムズ・ホスピタル |
がんを治療するための方法及び組成物
|
|
WO2017122130A1
(en)
|
2016-01-11 |
2017-07-20 |
Novartis Ag |
Immune-stimulating humanized monoclonal antibodies against human interleukin-2, and fusion proteins thereof
|
|
US20200095301A1
(en)
|
2016-12-14 |
2020-03-26 |
The Board Of Trustees Of The Leland Stanford Junior University |
Il-13 superkine: immune cell targeting constructs and methods of use thereof
|
|
US10849960B2
(en)
|
2017-09-08 |
2020-12-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Synergistic combination of IL-4, interferon gamma, and interferon alpha in treating ovarian cancer
|
|
EP3694558B1
(en)
|
2017-10-10 |
2024-04-10 |
Medicenna Therapeutics Inc. |
Il-4-fusion formulations for treatment of central nervous system (cns) tumors
|
|
CN113728232A
(zh)
|
2019-02-07 |
2021-11-30 |
梅迪塞纳医疗股份有限公司 |
作为癌症中的生物标志物的il-4r
|
|
CN116390744A
(zh)
|
2020-06-24 |
2023-07-04 |
梅迪塞纳医疗股份有限公司 |
双功能性超级因子及其用途
|